As the opioid crisis dawned in the U.S., continuing educational material that doctors are required to review may have contributed to the burgeoning problem, according to a newly published study.
How so? The study compared a continuing medical education module, or course, that was funded by a drug maker that sold a fentanyl lollipop and lozenge with practice guidelines issued by a medical society. The scope of the two publications was not completely identical, but both focused on the use of opioids in treating non-cancer pain. And the study found the industry-funded course contained a “subtle bias.”
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
